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An early repolarization (ER) pattern in the ECG is charac-terized by a J-point elevation with or without ST-segment 
elevation as well as notching or slurring of the terminal part of 
the QRS complex. ER is a relatively common ECG finding, 
long considered to be benign. Recent studies point to an asso-
ciation of ER with the development of ventricular tachycardia 
(VT) and fibrillation (VF) leading to sudden cardiac death.1–4 
ER has been divided into 3 subtypes. Type 1 involves an ER 
pattern localized to the lateral leads. In type 2, the ER pattern 
is present in the inferior and inferolateral leads, and in type 3, 
it is present globally in the inferior, lateral, and anterior or right 
precordial leads. Individuals with type 1 rarely develop VT/VF. 
Type 2 is associated with a higher level of risk, and individuals 
displaying a type 3 ER have the highest risk for developing 
life-threatening arrhythmias, including electric storms.4
Clinical Perspective on p 142
Hypothermia is known to contribute to the development of 
prominent J waves leading to VT/VF.4–6 Current guidelines 
recommend mild therapeutic hypothermia to prevent neu-
rological damage following a cardiac arrest.7,8 The extent to 
which hypothermia contributes to arrhythmogenesis and the 
mechanisms involved are not well defined. Recent reports 
point to an association between ER and the development of 
VT/VF in the setting of hypothermia.9,10 The present study 
was designed to test the hypothesis that ER, by causing out-
ward shift in the balance of currents active during the early 
phases of the epicardial action potential (AP), exacerbates the 
response to hypothermia, thus leading to prominent J waves, 
phase 2 reentry, and VT/VF. In addition, we examine the 
© 2014 American Heart Association, Inc.
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Background—Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with 
early repolarization (ER) pattern. This study examines the cellular mechanisms underlying VT/VF associated with 
hypothermia in an experimental model of ER syndrome and examines the effectiveness of quinidine, cilostazol, and 
milrinone to prevent hypothermia-induced arrhythmias.
Methods and Results—Transmembrane action potentials were simultaneously recorded from 2 epicardial and 1 endocardial 
site of coronary-perfused canine left ventricular wedge preparations, together with a pseudo-ECG. A combination of 
NS5806 (3–10 μmol/L) and verapamil (1 μmol/L) was used to pharmacologically model the genetic mutations responsible 
for ER syndrome. Acetylcholine (3 μmol/L) was used to simulate increased parasympathetic tone, which is known to 
promote ER. In controls, lowering the temperature of the coronary perfusate to induce mild hypothermia (32°C–34°C) 
resulted in increased J-wave area on the ECG and accentuated epicardial action potential notch but no arrhythmic activity. 
In the setting of ER, hypothermia caused further accentuation of the epicardial action potential notch, leading to loss of 
the action potential dome at some sites but not others, thus creating the substrate for development of phase 2 reentry and 
VT/VF. Addition of the transient outward current antagonist quinidine (5 μmol/L) or the phosphodiesterase III inhibitors 
cilostazol (10 μmol/L) or milrinone (5 μmol/L) diminished the ER manifestations and prevented the hypothermia-
induced phase 2 reentry and VT/VF.
Conclusions—Hypothermia leads to VT/VF in the setting of ER by exaggerating repolarization abnormalities, leading 
to development of phase 2 reentry. Quinidine, cilostazol, and milrinone suppress the hypothermia-induced VT/VF by 
reversing the repolarization abnormalities.  (Circ Arrhythm Electrophysiol. 2014;7:134-142.)
Key Words: arrhythmia ◼ phosphodiesterase 3 inhibitors ◼ ST segment elevation ◼ sudden cardiac death  
◼ tachycardia, ventricular ◼ ventricular fibrillation
Received July 25, 2013; accepted December 23, 2013.
From the Masonic Medical Research Laboratory, Utica, NY (Z.G., I.K., B.P., V.V.N., C.A.); and Department of Pharmacology and Pharmacotherapy, 
University of Szeged, Szeged, Hungary (Z.G., I.K., B.P.).
The Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/doi:10.1161/CIRCEP.113.000919/-/DC1.
Correspondence to Charles Antzelevitch, PhD, FAHA, FHRS, FACC, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY. E-mail 
ca@mmrl.edu
Cellular Mechanism Underlying Hypothermia-Induced 
Ventricular Tachycardia/Ventricular Fibrillation in 
the Setting of Early Repolarization and the Protective 
Effect of Quinidine, Cilostazol, and Milrinone
Zsolt Gurabi, PhD; István Koncz, MD; Bence Patocskai, MD; Vladislav V. Nesterenko, PhD;  
Charles Antzelevitch, PhD, FAHA, FHRS, FACC
 by guest on February 19, 2014http://circep.ahajournals.org/Downloaded from 
Gurabi et al  Hypothermia-Induced VT/VF  135
hypothesis that pharmacological agents capable of producing 
an inward shift in the balance of current in the early phases of 
the epicardial AP, either by inhibiting transient outward cur-
rent (Ito; quinidine) or augmenting ICa (cilostazol and milri-
none), can protect against hypothermia-induced VT/VF in the 
setting of ER.
Methods
Arterially Perfused Wedge of Canine Left Ventricle
We used floating glass microelectrode techniques to record APs si-
multaneously from 2 epicardial (Epi1 and Epi2) and 1 endocardial 
site in coronary- perfused wedge preparations isolated from the infe-
rior and lateral regions of the canine left ventricle (LV), together with 
pseudo-ECG recorded across the bath along the endocardial–epicar-
dial axis. Detailed methods are provided in the Data Supplement. 
The Tyrode’s solution was warmed while passing through the heated 
coils to deliver the perfusate at 37°C. To simulate hypothermia, 
the solution was redirected to 2 coiled-perfusion lines in series im-
mersed in beakers filled with water, before reaching the tissues. We 
lowered the temperature of the perfusate to 32°C.
Measurements of AP Parameters
The epicardial AP notch magnitude (phase 1 magnitude/phase 0 am-
plitude×100), phase 0 to phase 2 interval (time between the first 2 
peaks of the derivative of the AP), as well as the notch index (notch 
magnitude×[Ph 0–Ph 2 interval]), which approximates the area of 
the notch, were measured in AP recordings as previously described 
(Figure 1).11
J-Wave Area Calculations
The area of the J wave was calculated as follows: The start of J wave 
was defined using derivative of the ECG signal. In case of clear 
separation, it was set at the time when this derivative is zero which 
corresponds to the notch between R wave and J wave. When this sep-
aration was not clearly visible, this time was set at the moment when 
the negative derivative attains its maximal value (ie, minimal rate of 
decline) after the maximal downslope of the R wave. The J-wave area 
was expressed as millivolt×millisecond (Figure 1).
Statistical Analysis
Results are presented as mean±SEM throughout the article. Statistical 
comparisons were made using Student t test for effect of hypothermia 
on action potential duration at 90% of repolarization, maximum epi-
cardial dispersion of repolarization, transmural dispersion of repo-
larization, notch index, notch magnitude, notch duration, and J wave 
area and effect of hypothermia on these parameters in the setting of 
ER (Table). One-way repeated measures ANOVA was used for effects 
of quinidine, cilostazol, and milrinone (Table), followed by pairwise 
comparisons corrected by Bonferroni method.
Results
Effects of Hypothermia in LV Wedge Preparation
In an initial series of 7 experiments, we examined the effects 
of hypothermia in coronary-perfused canine LV wedge prep-
arations. Lowering the temperature to 32°C to 34°C caused 
prolongation of AP durations and accentuation of the AP 
notch in the epicardium but not endocardium, thus augment-
ing the amplitude of the J wave (Figure 2, Table). Under 
baseline condition, lowering the temperature to 32°C failed 
to cause loss of the epicardial AP dome or to induce arrhyth-
mic activities.
Effects of Hypothermia in ER-Induced LV  
Wedge Preparation
Because vagal influences are known to accentuate the elec-
trocardiographic and arrhythmic manifestations of ER,12–14 
in a second series of experiments, we induced an ER pheno-
type using a combination of the Ito activator NS5806 (3–10 
μmol/L), the Ca2+ channel blocker verapamil (1 μmol/L), 
and acetylcholine (3 μmol/L) added to the coronary perfus-
ate. The combination accentuated the AP notch in epicar-
dium but not endocardium, thus leading to augmentation 
of the electrocardiographic J wave but no arrhythmia (Fig-
ure 3A). Hypothermia caused a further increase of J-wave 
area, notch magnitude, and notch index, leading to all-or-
none repolarization at the end of phase 1 of the epicardial 
AP. Loss of the epicardial AP dome at some sites but not 
others resulted in a prominent increase in epicardial disper-
sion of repolarization and transmural dispersion of repo-
larization. The voltage gradient between the abbreviated 
Figure 1. A and B, Method of quantitation of action 
potential (AP) and J-wave parameters. C, Measure-
ment of dispersion of AP repolarization. D, Mea-
surement of dispersion of repolarization when the 
AP dome is lost at 1 epicardial (Epi) site but not the 
other. APD90 indicates action potential duration at 
90% repolarization; EDR, epicardial dispersion of 
repolarization; Endo, endocardial; and TDR, trans-
mural dispersion of repolarization.
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epicardial AP and the relatively normal endocardial AP 
produced a prominent ST-segment elevation. A prominent 
AP duration gradient developed between sites displaying a 
normal AP dome and adjacent sites where the dome was 
lost, thus creating a vulnerable window within epicardium 
as well as between epicardium and endocardium across the 
ventricular wall. Propagation of the dome from regions at 
which it was maintained to regions, at which it was lost, 
caused local re-excitation via a phase 2 reentry mechanism, 
leading to the development of closely coupled extrasystoles 
and polymorphic VT/VF (Figure 3).
Similar results were obtained in 12 experiments. Composite 
of the AP and electrocardiographic parameters are presented 
in Figure 3 and the Table.
Figure 3. Arrhythmogenic effect of hypothermia in 
the setting of early repolarization (ER). A, Traces 
recorded at 2 epicardial (Epi) and 1 endocardial 
(Endo) sites, together with a pseudo-ECG. The first 
grouping was recorded 30 minutes after addition 
of NS5806 (10 μmol/L), verapamil (1 μmol/L), and 
acetylcholine (ACh; 3 μmol/L) to the coronary per-
fusate at 37°C. The second grouping was recorded 
10 minutes after lowering of the perfusate to 32°C; 
hypothermia in the setting of ER leads to the 
development of phase 2 reentry and polymorphic 
ventricular tachycardia. B to F, Composite data 
showing the effect of lowering coronary perfusate 
temperature to 32°C on action potential duration 
at 90% repolarization (APD90), notch magnitude, 
notch index, and J-wave area. EDR indicates epi-
cardial dispersion of repolarization; and TDR, trans-
mural dispersion of repolarization. All recordings 
were obtained at a basic cycle length of 1000 ms. 
Results are mean±SEM. *P<0.05. †P<0.01 vs 37°C. 
n=12 for B, C, D, E, and F.
Figure 2. Effect of lowering the temperature (from 
37°C to 32°C) of the coronary perfusate in isolated 
canine left ventricular preparations under baseline 
conditions. A, Action potential traces simultane-
ously recorded from 2 epicardial (Epi) and 1 endo-
cardial (Endo) sites together with a pseudo-ECG 
at 37°C and at 32°C. B to E, Composite data 
showing the effect of lowering coronary perfusate 
temperature to 32°C on action potential duration 
at 90% repolarization (APD90), notch magnitude, 
notch index, and J-wave area. All recordings 
were obtained at a basic cycle length of 1000 ms. 
Results are mean±SEM. *P<0.05. †P<0.01 vs 37°C. 
n=7 for B, C, D, and E.
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Effect of Quinidine, Cilostazol, and Milrinone 
to Suppress and Prevent Hypothermia-Induced 
Arrhythmogenesis
Quinidine has been shown to restore transmural electric 
homogeneity and abort arrhythmic activity in the J-wave 
syndromes.2 In another series of 5 experiments, we tested 
the hypothesis that quinidine could prevent the hypothermia- 
induced VT/VF developing in the setting of ER attributable 
to its effect to reduce the Ito. VT/VF was first induced by 
exposure of the LV wedge to hypothermia+NS5806 (3–10 
μmol/L)+verapamil (1 μmol/L)+acetylcholine (3 μmol/L). 
Temperature was then restored to 37°C, at which point the 
arrhythmia subsided. Quinidine (5 μmol/L) was then added to 
the coronary perfusate, and hypothermia was reinduced. Quin-
idine (5 μmol/L) diminished the AP notch and J wave at 37°C 
and prevented loss of the epicardial AP dome and development 
of the repolarization abnormalities, thus preventing the devel-
opment of phase 2 reentry and VT/VF when temperature was 
reduced to 32°C (Figure 4). A similar effect of quinidine to 
prevent VT/VF was observed in 5 of 5 preparations exposed to 
hypothermia (Figure 4 and Table). In 2 experiments, quinidine 
(5–10 μmol/L) was added during the VT/VF episode at 32°C. 
In both cases, the drug suppressed all arrhythmic activity and 
restored electric homogeneity throughout the preparation.
In a final series of experiments, we examined the effective-
ness of the phosphodiesterase III inhibitors cilostazol and 
Figure 4. Quinidine prevents hypothermia-induced ventricular tachycardia and fibrillation (VT/VF) in the setting of early repolarization. 
A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG after exposure 
of the left ventricular wedge to NS5806 (3–10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). In the second grouping, the 
coronary perfusate temperature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 37°C, at which 
point the arrhythmia subsided (not shown). The third grouping was recorded after addition of quinidine (5 μmol/L) and reinduction of 
hypothermia. Quinidine (5 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of the Epi AP dome 
and development of the repolarization abnormalities, thus preventing the development of phase 2 reentry and VT/VF when temperature 
was reduced to 32°C. B to F, Composite data showing the effect of lowering coronary perfusate temperature to 32°C on AP duration 
at 90% repolarization (APD90), notch magnitude, notch index, and J-wave area in the presence and absence of quinidine. All recordings 
were obtained at a basic cycle length of 1000 ms. EDR indicates epicardial dispersion of repolarization; and TDR, transmural dispersion 
of repolarization. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. n=5 for B, C, D, E, and F.
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milrinone to prevent hypothermia-induced VT/VF in the set-
ting of ER. These agents are known to augment ICa via their 
action to increase cAMP. Here again, we first demonstrated 
the ability of the combination of provocative agents and 
hypothermia (32°C) to accentuate ER, thus creating a large 
epicardial and transmural dispersion of repolarization giving 
rise to phase 2 reentry and VT/VF. We then restored tem-
perature to 37°C, which reversed the repolarization abnor-
mality and suppressed VT/VF. The addition of cilostazol 
(10 μmol/L) or milrinone (5 μmol/L) reduced the epicardial 
AP notch at 37°C and prevented the repolarization abnor-
mality as well as the development of phase 2 reentry and 
Figure 5. Cilostazol prevents hypothermia-induced ventricular tachycardia and ventricular fibrillation (VT/VF) in the setting of early repo-
larization. A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG 
after exposure of the left ventricular wedge to NS5806 (3–10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). In the second 
grouping, the coronary perfusate temperature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 
37°C, at which point the arrhythmia subsided (not shown). The third grouping was recorded after addition of cilostazol (10 μmol/L) and 
reinduction of hypothermia. Cilostazol (10 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of 
the Epi AP dome and development of the repolarization abnormalities, thus preventing the development of phase 2 re-entry and VT/VF in 
5 of 7 preparations when temperature was reduced to 32°C. B to F, Composite data showing the effect of lowering coronary perfusate 
temperature to 32°C on AP duration at 90% repolarization (APD90), notch magnitude, notch index, and J-wave area in the presence and 
absence of cilostazol. EDR indicates epicardial dispersion of repolarization; TDR, transmural dispersion of repolarization. All recordings 
were obtained at a basic cycle length of 1000 ms. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. 
n=5 for B, C, D, E, and F.
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VT/VF when temperature was once again reduced to 32°C 
(Figures 5 and 6). Both agents prevented the hypothermia- 
induced increase in transmural dispersion of repolarization, 
epicardial dispersion of repolarization, epicardial AP notch 
magnitude, notch index, and J-wave area on pseudo-ECG. 
Cilostazol was successful in preventing the VT/VF in 5 of 
7 preparations. Similarly, milrinone (5 μmol/L) prevented 
the hypothermia-induced VT/VF in 5 of 7 preparations 
(Figures 5 and 6, Table).
Discussion
Therapeutic hypothermia is today widely used to prevent 
tissue injury secondary to cardiac arrest, ischemic stroke, 
traumatic brain and spinal cord injury, and neurogenic fever 
Figure 6. Milrinone prevents hypothermia-induced ventricular tachycardia and fibrillation (VT/VF) in the setting of early repolarization. 
A, The first grouping shows recordings from 2 epicardial (Epi) and 1 endocardial (Endo) sites, together with a pseudo-ECG after exposure 
of the left ventricular wedge to NS5806 (3–10 μmol/L)+verapamil (1 μmol/L)+acetylcholine (ACh; 3 μmol/L). The coronary perfusate tem-
perature was lowered to 32°C, leading to development of VT/VF. Temperature was then restored to 37°C, at which point the arrhythmia 
subsided (not shown). The third grouping was recorded after addition of milrinone (5 μmol/L) and reinduction of hypothermia. Milrinone 
(5 μmol/L) diminished the action potential (AP) notch and J wave at 37°C and prevented loss of the Epi AP dome and development of the 
repolarization abnormalities, thus preventing the development of phase 2 reentry and VT/VF in 5 or 7 preparations when temperature was 
reduced to 32°C. B to E, Composite data showing the effect of lowering coronary perfusate temperature to 32°C on AP duration at 90% 
repolarization (APD90), notch magnitude, notch index, and J-wave area in the presence and absence of milrinone. EDR indicates epicardial 
dispersion of repolarization; and TDR, transmural dispersion of repolarization. All recordings were obtained at a basic cycle length of 1000 
ms. Results are mean±SEM. *P<0.05. †P<0.01 vs NS5806+verapamil+ACh combination. n=5 for B, C, D, E, and F.
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following brain trauma. Subjects are generally cooled to a 
target temperature of 32°C to 34°C (90°F–93°F).15,16 In cases 
of cardiac arrest, the Hypothermia after Cardiac Arrest Study 
Group17 reported that 55% of 137 patients in the hypother-
mia group experienced favorable outcomes, compared with 
only 39% in the group that received standard care follow-
ing resuscitation. Among the adverse events encountered 
with therapeutic hypothermia is the development of cardiac 
arrhythmias.9,10 Hypothermia’s adverse events increase in 
severity the lower a patient’s body temperature is reduced. 
The accepted medical standard is to not drop <32°C (90°F).18
The factors that predispose to hypothermia-induced 
arrhythmogenesis and the mechanisms involved are poorly 
understood. Recent studies report an association between 
ER and the development of hypothermia-induced VT/VF.9,10 
The present study recapitulates this clinical phenomenon in 
an experimental model consisting of the canine LV coro-
nary-perfused LV wedge preparation, provides a mechanis-
tic understanding of the cellular basis for the development 
of VT/VF in the setting of ER and hypothermia, and iden-
tifies potential therapeutic agents that may be useful in 
suppressing or preventing the development of hypothermia-
induced VT/VF.
Mechanism of Hypothermia-Induced Arrhythmias 
in Patients With ER Syndrome
The J-wave syndrome, which includes both Brugada and 
ER syndromes, has been associated with genetic defects that 
cause a gain of function of Ito and a loss of function of ICa 
among many others.4 Both syndromes are also known to be 
aggravated by increased vagal tone.12,13 In this study, we phar-
macologically mimicked these genetic and autonomic factors 
to create ER using the Ito agonist NS5806 (3–10 μmol/L), 
ICa antagonist verapamil (1 μmol/L), and acetylcholine (3 
μmol/L). Acetylcholine contributes to the generation of the 
ER syndrome phenotype by causing both indirect (via accen-
tuated antagonism) and direct use-dependent inhibition of 
ICa.
19
 Litovsky and Antzelevitch19 demonstrated in 1990 the 
ability of acetylcholine to accentuate thee epicardial AP notch 
and to cause loss of AP dome.
Under baseline conditions, lowering temperature to 32°C 
caused the appearance of prominent J wave in the ECG 
attributable to accentuation of the epicardial AP notch. In the 
absence of provocative agents designed to generate an ER pat-
tern in the ECG, no arrhythmic activity was observed in any 
of the preparations. After the generation of the ER phenotype, 
relatively mild hypothermia (32°C–34°C) caused all-or-none 
repolarization, leading to loss of the AP dome at some epi-
cardial sites but not others. This resulted in dispersion of AP 
repolarization both within epicardium and between epicar-
dium and endocardium. Propagation of the AP dome, from 
sites at which the dome was maintained to sites at which it was 
lost, caused local re-excitation via a phase 2 reentry mecha-
nism, leading to the development of closely coupled extrasys-
toles and VT/VF.
Consistent with these observations is the demonstration 
by Nishida et al20 that vagal nerve stimulation accentuates 
the hypothermia-induced spike and dome AP morphology in 
canine epicardium.
Hypothermia is thought to accentuate the AP notch attribut-
able to the difference in the Q10 for activation of Ito and ICa. 
The greater slowing of ICa activation leaves Ito less opposed, 
thus accentuating phase 1 repolarization and the AP notch. 
Thus, an effective strategy to reduce the impact of hypother-
mia would be to either reduce Ito or augment ICa, thus pro-
ducing an inward shift in the balance of current during the 
early phase of the AP. In 3 experimental series, we tested this 
hypothesis by pretreating the preparations with either quini-
dine to block Ito or cilostazol and milrinone to augment ICa.
Potential Therapeutic Interventions
In support of our hypothesis, quinidine (5 μmol/L) proved 
capable of both suppressing and preventing the hypothermia- 
induced VT/VF in all preparations in which the drug was 
tested. Cilostazol (10 μmol/L) and milrinone (5 μmol/L) were 
effective in preventing the hypothermia-induced VT/VF in 
most but not all preparations. These agents increase ICa sec-
ondary to an increase in cAMP. It is noteworthy that cilostazol 
was reported to be able to prevent VT/VF in a patient with ER 
syndrome for an extended period of time.21 A beneficial effect 
of milrinone has as yet not been reported.
Conclusions
The present study demonstrates the effect of hypothermia to 
accentuate repolarization abnormalities within the LV epicar-
dium and that in the setting of ER, this effect of hypothermia 
is accentuated leading to the development of phase 2 reen-
try and VT/VF. We also provide support for the hypothesis 
that agents capable of producing an inward shift in the bal-
ance of current during the early phases of the AP can exert 
a protective and/or ameliorative effect. Quinidine, by virtue 
of its Ito inhibition, and cilostazol and milrinone, by virtue of 
their effects to augment ICa, are effective in partially reversing 
the hypothermia-induced repolarization abnormalities, thus 
restoring electric homogeneity and abolishing the arrhythmo-
genic substrate.
Study Limitations
As with all data derived from experimental animal models, 
extrapolation of the data from in vitro models to the clinic 
must be done with great care.
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CLINICAL PERSPECTIVE 
The pathogenicity associated with the presence of an early repolarization (ER) pattern in the ECG has been mired in contro-
versy. Although an ER pattern is considered to be largely benign, a growing number of case–control and population-based 
studies have demonstrated increased prevalence of ER pattern, particularly in inferior and inferolateral leads, among patients 
with idiopathic ventricular fibrillation (VF), thus providing clinical evidence in support of experimental studies showing a 
link between ER pattern in the ECG and life-threatening cardiac arrhythmias The pathogenicity of ER has been elusive, in 
part, because it remains subclinical in the absence of environmental triggers or comorbidities. Several recent studies have 
shown that an ER pattern in the ECG before a myocardial infarction predisposes an individual to life-threatening arrhythmias 
during and after an acute myocardial infarction. Other studies point to hypothermia as a trigger. Current guidelines recom-
mend mild therapeutic hypothermia to prevent neurological damage following a cardiac arrest. Recent reports, however, 
point to increased prevalence of hypothermia-induced ventricular tachycardia/VF in patients with an ER pattern. The present 
study examines the mechanisms involved as well as pharmacological strategies to minimize the risk of hypothermia-induced 
ventricular tachycardia/VF. Our experimental data obtained using coronary-perfused canine left ventricular wedge prepara-
tions in which ER is induced by pharmacologically mimicking the effect of genetic mutations responsible for ER syndrome 
indicate that hypothermia leads to ventricular tachycardia/VF in the setting of ER by exaggerating repolarization abnormali-
ties, leading to development of phase 2 reentry. Quinidine, cilostazol, and milrinone all suppress the hypothermia-induced 
ventricular tachycardia/VF by reversing these repolarization abnormalities.
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SUPPLEMENTAL MATERIAL 
 
 
Methods 
All experiments were carried out in compliance with the Guide for Care and Use of 
Laboratory Animals published by the National Institutes of Health (NIH publication No 85-23, 
Revised 1996) and approved by the Institutional Animal Care and Use Committee.  We used 
mongrel dogs weighing 20–35 kg of either sex. The chest was opened via a left thoracotomy and 
the heart was excised. Transmural wedge preparations with dimensions of up to 32 x 20 x 15 mm 
were dissected from the LV wall. The preparations were cannulated via a distal diagonal branch 
of the left anterior descending coronary artery, or a left marginal branch of the circumflex artery, 
or a branch of the posterior descending artery and perfused with cardioplegic solution (Tyrode’s 
containing 12 mmol/L KCl).  Non-perfused regions of the tissue were removed using a razor 
blade.  The preparations were then placed in a tissue bath and perfused with oxygenated 
Tyrode’s solution (mM): NaCl 129, KCl 4, NaH2PO4 0.9, NaHCO3 20, CaCl2 1.8, MgSO4 0.5, 
glucose 5.5, pH 7.4. The perfusate was delivered using a peristaltic pump (Masterflex peristaltic 
pump, Cole Parmer Instrument Co, Niles, Illinois) at a constant flow rate at 12-14 mL/min 
warmed to 37±0.5°C.  
The preparations were equilibrated in the tissue bath until electrically stable, usually 1 
hour. Pacing stimuli were delivered to the endocardial surface basic cycle length of 1000 ms 
using bipolar silver electrodes insulated except at the tips. The temperature of the perfusate was 
controlled by a heating bath associated with a glass condenser, a tube internally coiled within a 
wide cylindrical housing.  The Tyrode’s solution was warmed while passing through the heated 
coils to deliver the perfusate at 37°C.  To simulate hypothermia, the solution was redirected to 
two coiled-perfusion lines in series immersed in beakers filled with water, before reaching the 
tissues.  We lowered the temperature of the perfusate to 32°C.  
A transmural ECG was recorded using two electrodes consisting of AgCl half cells 
placed in the tissue bath, 1.0 to 1.5 cm from the Epi and Endo surfaces of the preparation, along 
the same axis as the transmembrane recordings (Epi electrode is connected to the positive input 
of the ECG amplifier). Transmembrane APs were simultaneously recorded from two Epi sites 
(Epi 1 and Epi 2; Epi1-Epi2 distance was approx. 10-20 mm) and one Endo site with the use of 
floating microelectrodes (DC resistance=10 to 20 MΩ) filled with 2.7 mol/L KCl, each 
connected to a high-input impedance amplifier. Impalements were obtained from the Epi and 
Endo surfaces of the preparation at positions approximating the transmural axis of the ECG 
recording. Spike 2 for Windows (Cambridge Electronic Design, Cambridge, UK) was used to 
record and analyze the ECG and the AP.  NS 5806, cilostazol and milrinone were dissolved in 
dimethyl sulphoxide (DMSO); acetylcholine, verapamil HCl, quinidine, were dissolved in 
distilled water (10 mM stock). DMSO controls were performed to ensure the absence of an effect 
of the solvent. 
 
